These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 9827230

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.
    Rice GP, Filippi M, Comi G.
    Neurology; 2000 Mar 14; 54(5):1145-55. PubMed ID: 10720289
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
    Mitosek-Szewczyk K, Tabarkiewicz J, Wilczynska B, Lobejko K, Berbecki J, Nastaj M, Dworzanska E, Kolodziejczyk B, Stelmasiak Z, Rolinski J.
    J Neurol Sci; 2013 Sep 15; 332(1-2):35-40. PubMed ID: 23835090
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Sep 15; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 11. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study.
    Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M, Grieb P.
    Mult Scler; 2009 Jun 15; 15(6):767-70. PubMed ID: 19482866
    [Abstract] [Full Text] [Related]

  • 12. Hematological effects of intermittent 2-hour infusions of cladribine in multiple sclerosis patients: a comparison of 2 dosage patterns.
    Grieb P, Kamienowski J, Janisz M, Kuśnierczyk P, Kawiak J, Hoser G, Chrapusta SJ.
    Int J Hematol; 2001 Dec 15; 74(4):421-7. PubMed ID: 11794698
    [Abstract] [Full Text] [Related]

  • 13. Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
    Giovannoni G, Coyle PK, Vermersch P, Walker B, Aldridge J, Nolting A, Galazka A, Lemieux C, Leist TP.
    Front Immunol; 2021 Dec 15; 12():763433. PubMed ID: 35003076
    [Abstract] [Full Text] [Related]

  • 14. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):416-26. PubMed ID: 20089960
    [Abstract] [Full Text] [Related]

  • 15. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
    Fleischer V, Friedrich M, Rezk A, Bühler U, Witsch E, Uphaus T, Bittner S, Groppa S, Tackenberg B, Bar-Or A, Zipp F, Luessi F.
    Mult Scler; 2018 Apr 04; 24(5):632-641. PubMed ID: 28436295
    [Abstract] [Full Text] [Related]

  • 16. The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial.
    Schirmer M, Mur E, Pfeiffer KP, Thaler J, Konwalinka G.
    Scand J Rheumatol; 1997 Apr 04; 26(5):376-9. PubMed ID: 9385350
    [Abstract] [Full Text] [Related]

  • 17. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
    Mult Scler Relat Disord; 2019 Apr 04; 29():157-167. PubMed ID: 30885374
    [Abstract] [Full Text] [Related]

  • 18. Marrow suppression produced by repeated doses of cladribine.
    Beutler E, Koziol JA, McMillan R, Sipe JC, Romine JS, Carrera CJ.
    Acta Haematol; 1994 Apr 04; 91(1):10-5. PubMed ID: 8171930
    [Abstract] [Full Text] [Related]

  • 19. Development of oral cladribine for the treatment of multiple sclerosis.
    Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC.
    J Neurol; 2010 Feb 04; 257(2):163-70. PubMed ID: 19921304
    [Abstract] [Full Text] [Related]

  • 20. Cladribine in treatment of chronic progressive multiple sclerosis.
    Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E.
    Lancet; 1994 Jul 02; 344(8914):9-13. PubMed ID: 7912347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.